Acute intermittent porphyria: Biochemical and clinical analysis in the Argentinean population

Clinica Chimica Acta

Volumn 288, Issue 1-2, 1999, Pages 63-71

  De Siervi, Adriana ^a   Rossetti, María V ^a   Parera, Victoria E ^a   Mendez, Manuel ^a   Varela, Laura S ^a   Batlle, Alcira M Del C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Acute intermittent porphyria; Argentinean population; Biochemical analysis; Porphyrinogenic agents

Indexed keywords

AMPHETAMINE DERIVATIVE; ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; COCAINE; DIURETIC AGENT; ERYTHROMYCIN; HEME; PORPHYRIN; SULFONAMIDE;

ACUTE INTERMITTENT PORPHYRIA; ADULT; ARGENTINA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EPIDEMIOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE;

ADULT; ARGENTINA; FEMALE; HUMANS; MALE; MIDDLE AGED; PORPHYRIA, ACUTE INTERMITTENT; PREVALENCE; SEX FACTORS;

EID: 0032826679     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(99)00139-4     Document Type: Article

References (24)

1. Strand LJ, Felsher BF, Redeker AG, Marver HS. Heme biosynthesis in intermittent acute porphyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased δ-aminolaevulinic acid synthetase activity. Proc Natl Acad Sci USA 1970;67:1315-20.
2. Anderson PM, Reddy RM, Anderson KE, Desnick RJ. Characterization of the porphobilinogen deaminase deficiency in acute intermittent porphyria: Immunologic evidence for heterogeneity of the genetic defect. J Clin Invest 1981;68:1-12.
3. Llewellyn DH, Elder GH, Kalsheker NA et al. DNA polymorphism of the human porphobilinogen deaminase gene in acute intermittent porphyria. Lancet 1987;2:706-8.
4. Delfau MH, Picat C, de Rooij FWM et al. Two different point G to A mutations in exon 10 of the porphobilinogen deaminase gene are responsible for acute intermittent porphyria. J Clin Invest 1990;86:1511-6.
5. Boon FFL, Ellis C. Acute intermittent porphyria in a children's psychiatric hospital. J Am Acad Child Adolesc Psychiatry 1989;28:606-9.
6. Badcock NR, O'Reilly DD, Zoanetti GD. Childhood porphyrias: implications and treatments. Clin Chem 1993;39:1334-40.
7. Mandoki MW, Sumner GS. Psychiatric manifestations of hereditary coproporphyria in a child. J Nerv Ment Dis 1994;182:117-8.
8. Bonkowsky H, Schady W. Neurologic manifestations of acute porphyria. Semin Liver Dis 1982;2:108-24.
9. De Siervi A, Rossetti MV, Parera VE et al. Identification and Characterization of hydroxy-methylbilane synthase mutations causing acute intermittent porphyria: Evidence for an ancestral founder of the common G111R mutation. Am J Med Genet 1999; In press.
10. Mauzerall D, Granick S. The occurrence and determination of δ-aminolaevulic acid and porphobilinogen in urine. J Biol Chem 1956;219:435-46.
11. Batlle AM del C, Wider de Xifra EA, Stella AM. A simple method for measuring erythrocyte porphobilinogenase and its use in the diagnosis of acute intermittent porphyria. Int J Biochem 1978;9:871-6.
12. Tschudy DP, Valsamis M, Magnussen CR. Acute intermittent porphyria: clinical and selected research aspects. Ann Intern Med 1975;83:851-64.
13. Wetterberg L. A neuropsychiatrie and genetic investigation of acute intermittent porphyria, Stockholm: Svenska Bokforlaget/Norstedts, 1967.
14. Andersson C. Acute intermittent porphyria in Northern Sweden. A population-based study, 1997, Doctoral thesis, Arjeplog, Sweden.
15. Elder GH. Molecular genetics of disorders of haem biosynthesis. J Clin Pathol 1993;46:977-81.
16. Astrin KH, Desnick RJ. Molecular basis of acute intermittent porphyria: mutations and polymorphisms in the human hydroxymethylbilane synthase gene. Hum Mutation 1994;4:243-52.
17. Kappas A, Sassa S, Galbraith RA. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The inherited basis of metabolic disorder, New York: McGraw-Hill, 1989.
18. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992;71:1-13.
19. Thunell S, Andersson C, Carlmark B. Markers for vulnerability in acute porphyria. A hypothesis paper. Eur J Clin Chem Biochem 1992;33:179-94.
20. Crimslisk HL. The little imitator - porphyria: a neuropsychiatrie disorder. J Neurol Neurosurg Psychiatry 1997;62:319-28.
21. Welland FH, Hellman ES, Gaddis EM et al. Factors affecting the excretion of porphyrin precursors by patients with acute intermittent porphyria. Metabolism 1964;13:232-52.
22. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 1996;240(4):195-201.
23. Bjersing L, Andersson C, Lithner F. Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations. Cancer Epidemiol Biomarkers Prev 1996;5:393-7.
24. Jeans JB, Savik K, Gross CR et al. Mortality in patients with acute intermittent porphyria requiring hospitalisation: a United States case series. Am J Med Gen 1996;65:269-73.